<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811174</url>
  </required_header>
  <id_info>
    <org_study_id>GAM10-03</org_study_id>
    <nct_id>NCT00811174</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases</brief_title>
  <official_title>Clinical Study to Evaluate the Efficacy, Safety and Kinetics of Octagam 10% for Replacement Therapy in Primary Immunodeficiency Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Octagam is a human normal immunoglobulin (IGIV) solution for intravenous administration.
      Octagam 5% is currently registered in more than 60 countries. This study will evaluate the
      efficacy, safety and the kinetics of Octagam 10% for replacement therapy in primary
      immunodeficiency diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to investigate the safety of Octagam 10% in replacement
      therapy in PID and to compare the pharmacokinetic profile of Octagam 10% with that of the
      previously used Octagam 5%.

      The secondary objective is to investigate the efficacy of Octagam 10% in replacement therapy
      in PID by monitoring the rate of occurence of serious bacterial infections, the rate of other
      infections, the trough (pre-next-dose) levels of total serum IgG and IgG subclasses (IgG1,
      IgG2, IgG3 and IgG4), the trough (pre-next-dose) levels of selected antigen specific
      antibodies, the use of antibiotics, the rate of absence from school/ work, and the number of
      days in hospital.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to limited data available, efficacy, and PK analyses were not performed.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>During infusion or within 72 hours after end of infusion</time_frame>
    <description>Occurrence of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Serum Total IgG and IgG Subclasses (IgG1, IgG2, IgG3 and IgG4) and Pharmacokinetics of Specific Antibodies Against Defined Infectious Agents Comparing Octagam 5% Treatment With Octagam 10% Treatment</measure>
    <time_frame>after 6 months of treatment</time_frame>
    <description>Pharmacokinetics of serum total IgG and IgG subclasses (IgG1, IgG2, IgG3 and IgG4) and pharmacokinetics of specific antibodies against defined infectious agents comparing Octagam 5% treatment with Octagam 10% treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>during each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters (Hematology, Clinical Chemistry, Direct Coombs Test and Urin Analysis)</measure>
    <time_frame>at each treatment date (every three to four weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Viral Safety</measure>
    <time_frame>Every three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-next-dose Levels of Serum Total IgG</measure>
    <time_frame>before each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-next-dose Levels of IgG Subclasses (IgG1, IgG2, IgG3, IgG4) and Pre-next-dose Levels of Specific Antibodies Against Defined Infectious Agents</measure>
    <time_frame>before treatement 10 and 13 (of 13 or 17 treatments) and at the end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy (Number of Infections, Number of Missed Days at School/ Work, Number of Hospitalisation Days, and Use of Antibiotics)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Immunologic Deficiency Syndromes</condition>
  <arm_group>
    <arm_group_label>Octagam 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octagam 10%</intervention_name>
    <description>300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
    <arm_group_label>Octagam 10%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of primary immunodeficiency (acc. WHO)

          -  Previous treatment with commercial Octagam 5% every 3-4 weeks for at least 6 infusions
             intervals

          -  Documented IgG trough levels of the two previous infusions before enrollment with a
             value of at least 5.5 g/L for both

        Exclusion Criteria:

          -  Acute infection requiring intravenous antibiotic treatment within two weeks before
             screening

          -  Exposure to blood or any blood product or derivative other than commercially available
             Octagam 5%, within the past 3 months

          -  History of hypersensitivity to blood or plasma derived products

          -  Requirement of any routine premedication for IGIV treatment

          -  History of congenital impairment of pulmonary function

          -  Severe liver function impairment

          -  Severe renal function impairment or predisposition for acute renal failure

          -  History of autoimmune haemolytic anaemia

          -  History of diabetes mellitus

          -  Congestive heart failure NYHA III or IV

          -  Non-controlled arterial hypertension

          -  History of DVT or thrombotic complications with IGIV treatment

          -  Known infection with HIV, HCV or HBV

          -  Treatment with steroids, immunosuppressive or immunomodulatory drugs

          -  Planned vaccination during study period

          -  Pregnant or nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Frenzel, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Octapharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Barbara Pyringer at Octapharma/ Vienna/ Austria for information</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <results_first_submitted>July 25, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients previously treated with commercial Octagam 5% were to be enrolled in the study on the basis of the in- and exclusion criteria defined in the study protocol. Patients were to be enrolled only after written informed consent by the patient had been obtained.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Octagam 10%</title>
          <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsors Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated prematurely. Owing to the limited data available (only 5 patients enrolled, of whom 2 completed the study and 3 ended treatment prematurely), efficacy and PK analyses were not performed. The safety analysis did not yield any unexpected results suggestive of a change in the riskâ€“benefit evaluation of Octagam 10%.</population>
      <group_list>
        <group group_id="B1">
          <title>Octagam 10%</title>
          <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Occurrence of Adverse Events</description>
        <time_frame>During infusion or within 72 hours after end of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Occurrence of Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Serum Total IgG and IgG Subclasses (IgG1, IgG2, IgG3 and IgG4) and Pharmacokinetics of Specific Antibodies Against Defined Infectious Agents Comparing Octagam 5% Treatment With Octagam 10% Treatment</title>
        <description>Pharmacokinetics of serum total IgG and IgG subclasses (IgG1, IgG2, IgG3 and IgG4) and pharmacokinetics of specific antibodies against defined infectious agents comparing Octagam 5% treatment with Octagam 10% treatment</description>
        <time_frame>after 6 months of treatment</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Serum Total IgG and IgG Subclasses (IgG1, IgG2, IgG3 and IgG4) and Pharmacokinetics of Specific Antibodies Against Defined Infectious Agents Comparing Octagam 5% Treatment With Octagam 10% Treatment</title>
          <description>Pharmacokinetics of serum total IgG and IgG subclasses (IgG1, IgG2, IgG3 and IgG4) and pharmacokinetics of specific antibodies against defined infectious agents comparing Octagam 5% treatment with Octagam 10% treatment</description>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>during each treatment</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameters (Hematology, Clinical Chemistry, Direct Coombs Test and Urin Analysis)</title>
        <time_frame>at each treatment date (every three to four weeks)</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameters (Hematology, Clinical Chemistry, Direct Coombs Test and Urin Analysis)</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Viral Safety</title>
        <time_frame>Every three months</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Viral Safety</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-next-dose Levels of Serum Total IgG</title>
        <time_frame>before each treatment</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-next-dose Levels of Serum Total IgG</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-next-dose Levels of IgG Subclasses (IgG1, IgG2, IgG3, IgG4) and Pre-next-dose Levels of Specific Antibodies Against Defined Infectious Agents</title>
        <time_frame>before treatement 10 and 13 (of 13 or 17 treatments) and at the end</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-next-dose Levels of IgG Subclasses (IgG1, IgG2, IgG3, IgG4) and Pre-next-dose Levels of Specific Antibodies Against Defined Infectious Agents</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy (Number of Infections, Number of Missed Days at School/ Work, Number of Hospitalisation Days, and Use of Antibiotics)</title>
        <time_frame>12 months</time_frame>
        <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Octagam 10%</title>
            <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy (Number of Infections, Number of Missed Days at School/ Work, Number of Hospitalisation Days, and Use of Antibiotics)</title>
          <population>Due to premature termination of the study, data were unavailable and no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Months</time_frame>
      <desc>In summary, the assessment of adverse events, laboratory variables and other safety-related observations revealed no reasons for concern about the safety of Octagam 10%.</desc>
      <group_list>
        <group group_id="E1">
          <title>Octagam 10%</title>
          <description>Octagam 10% : 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>surgery for inguinal condyloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>upper respirotory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>pharyngolarynngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Eppolito</name_or_title>
      <organization>Octapharma</organization>
      <phone>201-604-1155</phone>
      <email>michael.eppolito@octapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

